While the primary goal of MEK inhibitors is indeed to directly suppress cancer cell growth by blocking aberrant MAPK signaling, emerging research has unveiled an intriguing secondary benefit: the induction of immunological effects within the tumor microenvironment. Here, MAP2K7 is linked to cancer.